Delivering on the promise of precision cancer medicine

Michael F Berger^{1

2}, Eliezer M Van Allen^{3

4}

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. evanallen@partners.org.
⁴ Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. evanallen@partners.org.

Editorial

Michael F Berger et al. Genome Med. 2016.

. 2016 Oct 25;8(1):110.

doi: 10.1186/s13073-016-0373-1.

Michael F Berger^{1

2}, Eliezer M Van Allen^{3

4}

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. evanallen@partners.org.
⁴ Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. evanallen@partners.org.

No abstract available

References

1. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. doi: 10.1056/NEJMoa1210093. - DOI - PMC - PubMed
1. Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. doi: 10.1056/NEJMoa0909530. - DOI - PubMed
1. Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. doi: 10.1056/NEJMoa1214886. - DOI - PubMed
1. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867. - DOI - PubMed
1. Van Allen EM, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8. doi: 10.1038/nm.3559. - DOI - PMC - PubMed